Litcius/Paper detail

The Johnson & Johnson Vaccine for COVID-19

Edward H. Livingston, Preeti Malani, C. Buddy Creech

2021JAMA142 citationsDOI

Abstract

This JAMA Patient Page explains how the Johnson & Johnson COVID-19 vaccine, likely to be the third SARS-CoV-2 vaccine approved for widespread use, uses an adenovirus 26 vector to deliver coronavirus DNA to host cells to produce spike proteins and safely and effectively induce immunity.

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakCoronavirusImmunityDNA vaccinationSpike ProteinImmunologyImmune systemImmunizationOutbreakDiseaseInfectious disease (medical specialty)PathologySARS-CoV-2 and COVID-19 Research
The Johnson & Johnson Vaccine for COVID-19 | Litcius